The summary is that NAD+ is limited for cancer cells, so NAD+ depletion could be a promising cancer therapy.

On the other hand, a recent paper shows that NAD+ replenishment reverts tumor resistance to immunotherapy, so those therapies shouldn't be combined.

https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)...